- Home
- JTAI vs SBFM Comparison
JTAI vs SBFM Comparison
Compare JTAI & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JTAI
- SBFM
- Stock Information
- Founded
- JTAI 2018
- SBFM 2006
- Country
- JTAI United States
- SBFM United States
- Employees
- JTAI N/A
- SBFM N/A
- Industry
- JTAI Blank Checks
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- JTAI Finance
- SBFM Health Care
- Exchange
- JTAI Nasdaq
- SBFM Nasdaq
- Market Cap
- JTAI 2.7M
- SBFM 3.7M
- IPO Year
- JTAI N/A
- SBFM N/A
- Fundamental
- Price
- JTAI $0.10
- SBFM $3.14
- Analyst Decision
- JTAI
- SBFM
- Analyst Count
- JTAI 0
- SBFM 0
- Target Price
- JTAI N/A
- SBFM N/A
- AVG Volume (30 Days)
- JTAI 97.0M
- SBFM 90.8K
- Earning Date
- JTAI 11-19-2024
- SBFM 11-11-2024
- Dividend Yield
- JTAI N/A
- SBFM N/A
- EPS Growth
- JTAI N/A
- SBFM N/A
- EPS
- JTAI N/A
- SBFM N/A
- Revenue
- JTAI $14,478,722.00
- SBFM $30,481,982.00
- Revenue This Year
- JTAI $42.02
- SBFM $86.70
- Revenue Next Year
- JTAI N/A
- SBFM $126.76
- P/E Ratio
- JTAI N/A
- SBFM N/A
- Revenue Growth
- JTAI N/A
- SBFM 109.82
- 52 Week Low
- JTAI $0.08
- SBFM $2.42
- 52 Week High
- JTAI $4.47
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- JTAI 45.81
- SBFM 52.62
- Support Level
- JTAI $0.09
- SBFM $2.85
- Resistance Level
- JTAI $0.15
- SBFM $3.05
- Average True Range (ATR)
- JTAI 0.03
- SBFM 0.14
- MACD
- JTAI 0.00
- SBFM 0.03
- Stochastic Oscillator
- JTAI 12.77
- SBFM 85.29
About JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as via Jet Token's leased and managed aircraft.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.